On Tuesday, March 31, FDA published a Request for Information seeking input on the use of digital health technologies (“DHTs”) in clinical investigations for drugs and biological products (the “RFI”). Building on commitments under PDUFA VII and prior Agency publications – including a March 2023 Discussion Paper and December 2023 Guidance – FDA’s Centers for
Latest Post
More Posts
5 Developments Digital Health Innovators Should Watch in 2026
FDA to Convene Advisory Committee Meeting on GenAI Mental Health Devices
Could FDA Model Master Files Facilitate Use of Third-Party AI Models in the Drug Life Cycle?
CMS & HHS Health IT Office Issue Request for Information on Digital Health Products and Health Technology Infrastructure
FDA Issues Final Guidance on Multiple Function Digital Health Software and Other Devices
Client Alert: FDA Issues Temporary Guidance on New CARES Act Provision Requiring Certain Device Notifications to CDRH
FDA Commitment to MCM Development Reflected in New Draft Guidance on Medical Countermeasure Priority Review Vouchers
Subscribe: Subscribe via RSS